Chief Commercial Officer exits Pulse Biosciences (PLSE) with no stated dispute

Rhea-AI Filing Summary

Pulse Biosciences, Inc. reported that its Chief Commercial Officer, Kevin P. Danahy, resigned from the company effective immediately on February 27, 2026. The company stated that his resignation was not due to any disagreement regarding operations, policies, practices, or accounting matters.

The filing notes that Mr. Danahy played an important role in senior management and in the company’s early commercialization efforts, and extends well wishes for his future endeavors.

Insights

Corporate governance analyst

Pulse Biosciences’ Chief Commercial Officer resigned abruptly, but the company cites no underlying dispute.

The resignation of Chief Commercial Officer Kevin P. Danahy, effective immediately, removes a key executive involved in early commercialization efforts. Leadership turnover at this level can affect execution, especially for companies still scaling commercial operations.

The company explicitly states the departure did not result from disagreements over operations, policies, practices, or accounting, which helps limit concerns about internal conflict or reporting issues. Future company communications and filings will clarify how responsibilities are reallocated and whether a successor is appointed.

false 0001625101 0001625101 2026-02-27 2026-02-27

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): February 27, 2026

Pulse Biosciences, Inc.
(Exact Name of Registrant as Specified in Its Charter)
Delaware	001-37744	46-5696597
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
601 Brickell Key Drive, Suite 1080
Miami, Florida 33131
(Address of Principal Executive Offices) (Zip Code)
510-906-4600
(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, If Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Trading Symbol(s)	Name of Each Exchange on Which Registered
Common stock, $0.001 par value per share	PLSE	The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.

On February 27, 2026, Kevin P. Danahy, the Chief Commercial Officer of Pulse Biosciences, Inc. (the “Company”) gave notice that he was resigning from the Company, effective immediately. Mr. Danahy’s resignation was not a result of any disagreement with the Company on any matter relating to its operations, policies, or practices, or to any issues regarding its accounting policies or practices. During his tenure at the Company, Mr. Danahy was an important part of senior management as well as the Company's early commercialization efforts, and we wish him well in his future endeavors.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number	Description
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	PULSE BIOSCIENCES, INC.
Date: February 27, 2026	By:	/s/ Paul A. LaViolette
		Paul A. LaViolette
		President and Chief Executive Officer (Principal Executive Officer)

FAQ

What executive change did Pulse Biosciences (PLSE) disclose in this 8-K?

Pulse Biosciences disclosed that its Chief Commercial Officer, Kevin P. Danahy, resigned effective immediately on February 27, 2026. The filing notes he was an important part of senior management and early commercialization efforts during his tenure with the company.

When was the resignation of Pulse Biosciences’ CCO Kevin Danahy effective?

The resignation of Chief Commercial Officer Kevin P. Danahy was effective immediately on February 27, 2026. This means he ceased serving in the role on the same date the notice was given and the 8-K was filed.

Did Kevin Danahy resign from Pulse Biosciences (PLSE) due to a disagreement?

According to the filing, Kevin P. Danahy’s resignation was not the result of any disagreement with Pulse Biosciences on operations, policies, practices, or accounting matters. The company emphasizes there were no such disputes underlying his decision to leave.

What role did Kevin Danahy play at Pulse Biosciences (PLSE)?

Kevin P. Danahy served as Chief Commercial Officer of Pulse Biosciences. The company states he was an important part of senior management and contributed to its early commercialization efforts, highlighting his involvement in bringing the company’s offerings to market.

How did Pulse Biosciences (PLSE) characterize Kevin Danahy’s departure?

Pulse Biosciences stated that Kevin P. Danahy’s resignation was not due to disagreements and recognized him as an important member of senior management. The company expressed appreciation for his contributions and wished him well in his future endeavors.

Filing Exhibits & Attachments

4 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.5 KB
• EX-101 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE 11.2 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 15.0 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 11.3 KB